Ticker Launch
Sign inTry it free

SPAC · Merger completed

Frazier Lifesciences Acquisition Corp

Business combination with NewAmsterdam Pharma Company B.V.

Frazier Lifesciences Acquisition Corp is a blank-check company (SPAC) that raised $120M in its initial public offering on Dec 10, 2020, listing on Nasdaq Capital Market. It completed its business combination with NewAmsterdam Pharma Company B.V. on Nov 22, 2022; the combined company is NewAmsterdam Pharma Company N.V. (NAMS). Goodwin Procter advised the SPAC and Kirkland & Ellis advised the underwriters on the IPO.

NewAmsterdam Pharma Company B.V. is a clinical-stage biopharmaceutical company working on treatments for metabolic diseases where traditional therapies have fallen short. Its lead candidate is obicetrapib, licensed to the Menarini Group for commercialization in Europe, with other rights retained.

Status
Merger completed
IPO date
Dec 10, 2020
IPO size
$120M
IPO exchange
Nasdaq Capital Market
Target
NewAmsterdam Pharma Company B.V.
Announced
Jul 25, 2022
Closed
Nov 22, 2022
Combined company
NewAmsterdam Pharma Company N.V. (NAMS)
SPAC counsel (IPO)
Goodwin Procter and Campbells
Underwriters' counsel (IPO)
Kirkland & Ellis

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2022